Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results
Claire Roddie(Cancer Institute (WIA)), Ruth J. Pepper(University College Hospital), Josefina Cortés-Hernández(Vall d'Hebron Hospital Universitari), Pere Barba(Universitat Autònoma de Barcelona), Yanqing Hu(Io Therapeutics (United States)), David Jayne(University of Cambridge), Davide Germano(NBE Therapeutics (Switzerland)), Ben Uttenthal(Cambridge University Hospitals NHS Foundation Trust), Maria Leandro(University College Hospital), Ben Parker(Manchester Royal Infirmary), Wolfram Brugger(University of Freiburg), Jose Andrés Román Ivorra(Hospital Universitari i Politècnic La Fe), Eleni Tholouli(Manchester Royal Infirmary), Silvia Basilico(NBE Therapeutics (Switzerland))
Cited by 0
Related Papers
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
|Arthritis & Rheumatism|2012|6.6k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
|New England Journal of Medicine|2010|1.7k
Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis
|Journal of the American Society of Nephrology|2007|1.1k